Clinical trials: Alcohol Withdrawal Syndrome
Alcohol-Induced Disorders
Magnesium After Alcohol Withdrawal Treatment
The primary purpose is to see if magnesium tablet supplementation will decrease elevated GGT enzyme activity in alcoholic patients immediately after they had been treated for alcohol withdrawal.
- Trial name
- NCT00325299
- Testing
- Magnesium
- Where
- Finland
- Volunteers
- 178 people
- Sponsor
- Finnish Foundation for Alcohol Studies
Alcohol Withdrawal, Alcohol Withdrawal Delirium
Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit
Our aim is to compare outcomes of patients with benzodiazepine-refractory alcohol withdrawal syndrome who are treated with either a phenobarbital-based or a lorazepam based protocol.
- Trial name
- PARTI (NCT04156464)
- Testing
- Phenobarbital, Lorazepam
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- OSF Healthcare System
Alcohol Withdrawal Syndrome
Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants
Complicated alcohol withdrawal syndrome (AWS) increases morbidity and mortality of hospitalized, medically ill patients. The Psychosomatic Medicine Service is commonly consulted to assist in the management of these patients when…
- Trial name
- NCT05438641
- Testing
- BZDP-Sparing Protocol, BZDP-Based Protocol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Acute Alcohol Withdrawal
Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal
This study is designed to evaluate dexmedetomidine as adjunctive therapy of severe alcohol withdrawal of medical ICU patients. Specifically, this study will assess whether adjunctive dexmedetomidine reduces the doses of…
- Trial name
- DATA (NCT00936377)
- Testing
- Dexmedetomidine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Colorado, Denver
Alcohol Withdrawal, Substance Use Disorders
NCARE, Transition to Recovery
This study tests the effectiveness of patient navigation for increasing enrollment in substance abuse treatment programs and preventing readmission to detoxification.
- Trial name
- NCT03737864
- Testing
- Patient navigation, Motivational interviewing (MI)
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- University of Colorado, Denver
Alcohol Abuse, Alcoholism
Consequences of At-risk Alcohol Consumption in ICU Patients
At-risk drinking is known to cause a high incidence of alcohol withdrawal syndrome which has a high impact on morbidity and mortality.
- Trial name
- NCT03565016
- Testing
- no interventional study
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Nantes University Hospital
Alcoholism, Substance-Related Disorders
Intranasal Oxytocin Effects in Alcohol Withdrawal and Dependence; Follow-up Study
This study is an assessment of the long-term effect of oxytocin nasal spray on alcohol withdrawal and dependence in adults admitted for detoxification of alcohol after 60 days and 1 year.
- Trial name
- NCT03339024
- Testing
- intranasal oxytocin spray, intranasal spray without oxytocin
- Where
- Norway
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Alcohol Use Disorder, Addiction
Portrayal of Hospital Alcohol Detoxification in France
Even if hospital alcohol detoxifications are frequent in France, their caracteristicscharacteristics remain unknown. The investigators aim to describe the clinical and paraclinical caracteristicscharacteristics of their patients…
- Conditions
- Alcohol Use Disorder, Addiction, Alcohol Withdrawal Syndrome
- Trial name
- Alcostop (NCT04973202)
- Testing
- Stay for alcohol detoxification
- Where
- France
- Volunteers
- 50,000 people
- Sponsor
- University Hospital, Montpellier
Alcohol Withdrawal Syndrome
Preventing Alcohol Withdrawal Syndrome With Oral Baclofen
Adult medical/surgical inpatient hospital care is more difficult and more expensive when complicated by alcohol dependency (AD), especially for patients who develop alcohol withdrawal syndrome (AWS).
- Trial name
- NCT02052440
- Testing
- Baclofen
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Denver Health and Hospital Authority
Alcohol Withdrawal Delirium, Alcohol Withdrawal
Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome
Severe acute alcohol withdrawal syndrome is a potentially life-threatening condition characterized by agitation, confusion, abnormal heart rhythms and seizures.
- Conditions
- Alcohol Withdrawal Delirium, Alcohol Withdrawal, Alcohol Withdrawal Seizures
- Trial name
- PHENOMANAL (NCT03586089)
- Testing
- Phenobarbital Sodium
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Unity Health Toronto
Alcohol Dependence
Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol Withdrawal
Alcohol dependence is accompanied by several neurological mechanisms involving neuronal plasticity and neoneurogenesis, requiring Brain Derived Neurotrophic factor (BDNF) synthesis.
- Trial name
- NCT01491347
- Where
- 4 sites in France
- Volunteers
- 389 people
- Sponsor
- Centre Hospitalier Esquirol
Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
This is a prospective, randomized, double-blind, placebo-controlled, parallel-group study of dexmedetomidine versus placebo, with lorazepam rescue, for the management of severe alcohol withdrawal syndrome (AWS) and alcohol…
- Conditions
- Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity, Alcohol Withdrawal Hallucinosis, Alcohol Withdrawal-Induced Delirium Tremens
- Trial name
- NCT01362205
- Testing
- Dexmedetomidine
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Denver Health and Hospital Authority
Alcohol Use Disorder, Alcohol Withdrawal
Bright Light Therapy During Residential Alcohol Withdrawal
This is a randomized controlled trial assessing the effectiveness of light therapy versus placebo in patients undergoing alcohol withdrawal.
- Trial name
- LUNA (NCT06878287)
- Testing
- Light exposure
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier St Anne
Alcohol Withdrawal Syndrome
The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS)
Although there are several tools that can be used to evaluate the severity of ongoing alcohol withdrawal syndrome (AWS), there is no available tool that can predict which patients are at risk for developing AWS at the time…
- Trial name
- PAWSS (NCT01637415)
- Where
- United States
- Volunteers
- 409 people, healthy volunteers welcome
- Sponsor
- Stanford University
Alcohol-related Liver Disease, Alcohol Dependence
Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
The lockdown consequent to Coronavirus outbreak has had a differential impact on the drinking behaviour on the general population.
- Conditions
- Alcohol-related Liver Disease, Alcohol Dependence, Alcohol Withdrawal, Addiction, Alcohol
- Trial name
- NCT04876443
- Testing
- Study questionnaire
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- King's College Hospital NHS Trust
Alcohol Use Disorder
Ambulatory Alcohol Detoxification With Remote Monitoring
This study is designed to examine the feasibility and impact of the use of remote monitoring devices during an outpatient ambulatory alcohol detoxification treatment for patients with alcohol use disorders.
- Trial name
- NCT03582150
- Testing
- Remote Monitoring with Ambulatory Detox
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Stanford University
Alcoholism, Substance-Related Disorders
Oxytocin and Alcohol Withdrawal and Dependence
This study evaluates the effect of oxytocin nasal spray on alcohol withdrawal and dependence in adults admitted for detoxification of alcohol, and during the following 4 weeks in an outpatient setting.
- Trial name
- NCT02903251
- Testing
- intranasal oxytocin spray, intranasal spray without oxytocin
- Where
- Norway
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Alcohol Withdrawal, Alcohol Abstinence
Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients
Alcohol withdrawal syndrome is a highly morbid condition affecting a substantial percentage of patients hospitalized who have alcohol use disorders, estimated at 5-6% of all hospitalized patients.
- Conditions
- Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
- Trial name
- NCT07810946
- Testing
- Sodium Acetate
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Colorado, Denver
Alcohol Withdrawal Syndrome
Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine
The goal of this study will aim to determine if adding phenobarbital or ketamine to a symptom-triggered benzodiazepine regimen decreases the rate of intensive care unit admissions during the treatment of alcohol withdrawal…
- Trial name
- PKAT (NCT03788889)
- Testing
- Ketamine, Phenobarbital, Lorazepam
- Sponsor
- Santa Barbara Cottage Hospital
Substance Withdrawal Syndrome
Process Evaluation Standardised Nurse-led Approach for Risk Screening and Decrease of Alcohol Withdrawal in ENT
In ear, nose, throat (ENT) and jaw surgery departments, up to 60% of patients suffer from alcohol dependence (Allen et al., 2009), and may develop an alcohol withdrawal syndrome (AWS) when undergoing sur-gery.
- Trial name
- NCT02782156
- Testing
- Process evaluation
- Where
- Switzerland
- Volunteers
- 89 people
- Sponsor
- University Hospital, Basel, Switzerland